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ABSTRACT 22 
The industrial application of Baeyer-Villiger monooxygenases is typically hindered by stability 23 
and cofactor regeneration considerations. Stability of biocatalysts can be improved by 24 
immobilization. The goal of this study was to evaluate the (co)-immobilization of a 25 
thermostable cyclohexanone monooxygenase from Thermocrispum municipale (TmCHMO) 26 
with a glucose dehydrogenase (GDH) from Thermoplasma acidophilum for NADPH cofactor 27 
regeneration.  28 
Both enzymes were immobilized on an amino-functionalized agarose-based support (MANA-29 
agarose). They were applied to the synthesis of 3,3,5-trimethylcyclohexanone for the synthesis 30 
of ε-caprolactone derivatives which are precursors of polyesters. The performances of the 31 
immobilized biocatalysts were evaluated in reutilization reactions with up to 15 cycles and 32 
compared to the corresponding soluble enzymes. Co-immobilization proved to provide the 33 
most efficient biocatalyst with an average conversion of 83% over 15 reutilization cycles 34 
leading to a 50-fold increase of the biocatalyst yield compared to the use of soluble enzymes 35 
which were applied in a fed-batch strategy.  36 
TmCHMO was immobilized for the first time, with very good retention of the activity 37 
throughout reutilization cycles. This immobilized biocatalyst contributes to the application of 38 
BVMOs in up-scaled biooxidation processes.  39 
Keywords:  biocatalyst immobilization, Baeyer-Villiger monooxygenase, lactone monomer, 40 
cofactor recycling, glucose dehydrogenase 41 
 42 
 43 
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1. INTRODUCTION 44 
Enzymatic reactions have been identified as a sustainable technology since they usually follow 45 
the rules of green chemistry.[1,2] Oxidative biocatalysis, and Baeyer-Villiger monooxygenases 46 
(BVMOs) in particular, is an alternative of lesser toxicity compared to chemical oxidation.[3] 47 
BVMOs are biocatalysts capable of catalyzing the oxidation of (cyclic) ketones by inserting 48 
one atom of oxygen in a C-C bond, therefore generating water as by-product. BVMOs can 49 
catalyze the oxidation of a wide range of cyclic ketones of various ring size including alkyl 50 
substituted ketones, as well as perform enantioselective sulfoxidation.[4-6] These oxidative 51 
enzymes have been applied to the synthesis of intermediates for the pharmaceutical industry,[7-52 
9] and chiral molecules for fine chemical and fragrances.[10] Additionally, several BVMOs 53 
have been identified as relevant biocatalyst for the synthesis of lactone as monomers for 54 
polymeric materials, for example, ε-caprolactone, either from whole-cell[11] or via a cascade 55 
reaction,[12] lauryl lactone,[13] a nitrile-substituted ε-caprolactone as precursor for 56 
polyamide,[14] and β,δ-trimethyl-ε-caprolactone (TMCL).[15,16] Alkyl substituted lactones 57 
are particularly interesting for the synthesis of polyesters with low glass transition temperature 58 
(Tg < 0 °C in general).[17] This property enables applications such as biodegradable 59 
plasticizers[18] or encapsulating agents for coating formulations[19] with polymers from 60 
TMCL for example. 61 
The applicability of BVMOs is however hindered by their lack of robustness, either due to 62 
thermostability or to limited stability in the presence of organic solvents. Using protein 63 
engineering, several mutants of cyclohexanone monooxygenase with improved thermostability 64 
were created.[20-22] The discovery of new thermostable BVMOs contributes to the 65 
development of their applicability in biotransformations.[23-26] Recently, a cyclohexanone 66 
monooxygenase from Thermocrispum municipale DSM 44069 (TmCHMO; EC 1.14.13.22) 67 
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was identified as being particularly relevant for the preparation of lactones as polymeric 68 
building blocks due to its high thermostability, good resistance to organic solvents, and broad 69 
substrate scope towards cyclic ketones.[27,28] 70 
Although TmCHMO has already been applied for the synthesis of ε-caprolactone derivatives 71 
from 3,3,5-trimethylcyclohexane, using either a self-sufficient fused biocatalyst[15] or a 72 
glucose dehydrogenase to regenerate the NADPH co-factor,[16] this enzyme has not yet been 73 
immobilized. Immobilization of whole-cells or isolated enzymes is indeed known to increase 74 
the operational stability of enzymes. Additionally, immobilization has several advantages 75 
including facilitating the recovery of the biocatalyst, decreasing the costs of downstream 76 
processing, and potentially decreasing the enzyme cost per kilogram of product, provided that 77 
the immobilized biocatalysts maintain their activity throughout the reuses.[29,30] 78 
So far, isolated BVMOs have mostly been immobilized to polymeric supports by covalent 79 
binding.[31] For example, a cyclohexanone monooxygenase from Acinetobacter calcoaceticus 80 
(AcCHMO) was immobilized on Eupergit  (polyacrylamide based supported beads) via 81 
covalent binding with a glucose 6-phosphate dehydrogenase for the synthesis of chiral lactone 82 
building blocks.[32] Fusions of AcCHMO with a polyol dehydrogenase were similarly 83 
immobilized for the synthesis of ε-caprolactone.[33] The immobilized biocatalyst, however, 84 
displayed a low stability on the support and a poor operational stability. Recently, MANA-85 
agarose (monoaminoethyl-N-aminoethyl)-agarose was identified as a suitable support for the 86 
immobilization of a fused AcCHMO-phosphite dehydrogenase (AcCHMO-PTDH).[34] For 87 
this enzyme, a higher retained activity was achieved with metal-chelate supports such as Ni-88 
iminodiacetic acid (Ni-IDA) and Co-IDA.[34]  89 
In this article, our goal is to expand the use of immobilized BVMOs and evaluate them for the 90 
synthesis of lactones as polymeric building blocks. The immobilization of TmCHMO and a 91 
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glucose dehydrogenase from Thermoplasma acidophilum (EC 1.1.1.47) (GDH-Tac) are 92 
described with the aim of oxidizing 3,3,5-trimethylcyclohexanone to alkyl substituted ε-93 
caprolactone derivatives (Figure 1). The enzymes were immobilized on a MANA-agarose 94 
support, either separately or co-immobilized on the same support, by covalent bonding. The 95 
performances of the immobilized enzymes were evaluated in over 15 repeated biooxidation 96 
cycles and compared to the corresponding soluble enzymes.  97 
2. EXPERIMENTAL 98 
2.1.Chemicals. 99 
3,3,5-Trimethylcyclohexanone (98%, Sigma-Aldrich), methanol (Biosolve), (+)-glucose 100 
(>99%, Alfa Aesar) were used as received. High-density aminoethyl 4BCL agarose (MANA-101 
agarose, Agarose Beads Technologies) was stored at 4 ˚C. β-Nicotinamide adenine 102 
dinucleotide phosphate disodium salt (NADP+, 97%, Alfa Aesar), and N-(3-103 
dimethylaminopropyl)-N′-ethylcarbodiimide (EDC, ≥97%, Sigma-Aldrich) were stored at -104 
20 ˚C. TmCHMO and GDH-Tac were produced and supplied by InnoSyn BV (Geleen, The 105 
Netherlands). 106 
2.2.TmCHMO and GDH-Tac activity assays   107 
TmCHMO activity in the CFE was determined spectrophotometrically following NAPDH 108 
consumption at 340 nm (Ɛ = 6.22 mM-1 cm-1) with cyclohexanone as a substrate. The mixture 109 
contained Tris-HCl (50 mM, pH 8.5), cyclohexanone (0.5 mM), NADPH (0.1 mM). One unit 110 
of TmCHMO (U) was defined as the amount of enzyme required to catalyze the conversion of 111 
1 µmol of NADPH to NADP+ per min at 20 °C and pH 8.5.[34] 112 
GDH-Tac activity was determined spectrophotometrically at 340 nm following the NADP+ (Ɛ 113 
= 6.22 mM-1 cm-1, 400 µM) consumption using D-Glucose (200 mM) as substrate and sodium 114 
phosphate buffer 100 mM pH 8.0.[35] The basal production of NADPH by unspecific enzymes 115 
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present in the lysate was determined by this same test but avoiding the addition of substrate 116 
and adding buffer instead. This production rate is subtracted from the measurement with D-117 
glucose. One unit of activity (U) was defined as the enzyme required to convert 1 µmol of 118 
NADP+ per minute at those given conditions (30 ºC, pH 8.0). The absorbance was recorded 119 
using a spectrophotometer Cary 50 Bio UV-visible (Palo Alto, USA).  120 
2.3.Preparation of immobilized TmCHMO and immobilized GDH-Tac 121 
The general procedure for the covalent immobilization of the enzymes on MANA-agarose 122 
(density: 1.07 g mL-1) comprised three main steps: i) the ionic adsorption of the enzyme to the 123 
support, ii) the addition of N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) as an 124 
activating agent to promote amide bond formation between the support and the enzyme, and 125 
iii) the addition of NaCl to desorb all the enzyme that was not covalently bound to the support. 126 
After the immobilization, the derivatives were washed carefully. 127 
The immobilization of TmCHMO was carried out by suspending the support in 25 mM MES 128 
buffer (pH 6.0); then the enzyme was added to the suspension and left to adsorb ionically to 129 
the support for 0.25 h. After that time, EDC was added to final concentrations of 25 or 35 mM 130 
and left for 2 h. Finally, NaCl was added to a final concentration of 1 M and incubated for 1 h. 131 
The immobilized derivative was washed with distilled water and filtered. 132 
The immobilization of GDH-Tac was performed in 50 mM sodium phosphate buffer (pH 6.0). 133 
The ionic adsorption step was completed after 0.5 h. A 200mM stock solution of EDC was 134 
prepared, the pH was adjusted to 6.0 with HCl; different volumes were added to get final 135 
concentrations of 1, 3, 5, 10 or 15 mM and incubated for 1h. Afterwards, NaCl was added to a 136 
final concentration of 0.5 M and incubated for 0.5 h. Lastly, the support was washed gently 137 
with 100 mM sodium phosphate buffer (pH 8.0) and filtered. 138 
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For the co-immobilization of TmCHMO and GDH-Tac, the support was suspended in 50 mM 139 
sodium phosphate buffer (pH 6.0); both enzymes were added and incubated 0.25 h. After the 140 
ionic step was completed, EDC was added to final concentrations of 10 or 20 mM and 141 
incubated 1 h. NaCl was added to a final concentration of 1M. The derivative was washed with 142 
distilled water and filtered. 143 
The characterization of the immobilization was carried out by measuring the activity of the 144 
supernatant and the suspension throughout the entire process, in order to determine the retained 145 
activity (Equation (1)) and immobilization yield (Equation (2)). TmCHMO and GDH-Tac 146 
immobilized on MANA-agarose were stored at 4 °C prior to use. 147 
Retained activity (%)=
Final suspension activity - Final supernatant activity
Initial supernatant activity
×100               (1) 148 
Immobilization yield (%)= 
Initial supernatant activity -Final supernatant activity
Initial supernatant activity
 ×100    (2) 149 
2.4.Determination of enzyme content 150 
The cell lysate was pre-clarified by centrifugation (3220 g for 15 min.), and the total protein 151 
content was determined by means of a Bradford Protein Assay Kit (Thermo Fisher Scientific, 152 
Waltham, USA) using bovine serum albumin as standard. 153 
Enzyme content was assessed using sodium dodecyl sulphate polyacrylamide gel 154 
electrophoresis (SDS-PAGE) (NuPage 12%, Invitrogen, USA) ran in a Mini-PROTEAN II 155 
apparatus (BioRad, USA) following the protocol of Laemmli et al.[36] Low range protein 156 
markers were used for molecular weight determination. Gels were stained using Coomassie 157 
G250 colloidal stain solution (34% v v-1 ethanol, 2% v v-1 H3PO4, 17% w v
-1 NH4SO4 and 158 
0.066% Coomassie G250) and Image LABTM software (BioRad, USA) was used for image 159 
processing. 160 
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2.5. Determination of the reaction progress for biocatalyzed reactions using GC-FID  161 
The substrate and product concentration were determined by GC-FID analysis in triplicate. 162 
Aliquots of the reaction mixture (50 μL) were taken and diluted in acetonitrile (950 μL). The 163 
sample was centrifuged using an Eppendorf centrifuge 5424 to remove precipitated protein and 164 
analyzed by gas chromatography (GC-FID). The concentration of substrate and lactones were 165 
determined using calibration curves. GC-FID analyses were performed using a Shimadzu GC-166 
2010 Plus Gas Chromatograph with a hydrogen flame-ionization detector and an SPB-1 167 
capillary column (30 m × 0.25 μm × 0.25 mm inner diameter). For kinetics, the following 168 
program was used: starting temperature of 60 ˚C maintained for 2 minutes, temperature 169 
increased to 200 ˚ C at a heating rate of 15 ˚C min-1 and then maintained at 200 ˚ C for 2 minutes, 170 
and temperature finally increased to 320 ˚C at a heating rate of 20 ˚C min-1 and maintained at 171 
320 ˚ C for 2 minutes (sample injected at 250 ˚ C, with a split ratio of 10, 2 μL injection volume). 172 
The following retention times were observed for kinetic samples measured from the reaction 173 
mixture: 6.83 min for the substrate 1, 9.25 min and 9.36 min for the lactones 1b and 1a (Figure 174 
1). 175 
2.6.Reaction set-up and reaction conditions 176 
The reactions were performed with a Metrohm 887 Titrino Plus titration apparatus. The pH 177 
was monitored and adjusted to pH 8.0 by automatic addition of a solution of NaOH (1 M). The 178 
reaction was performed in a double walled-glass and the temperature was maintained to 30 °C. 179 
The reactions were performed in potassium phosphate buffer (25 mM), at pH 8.0. The reaction 180 
was stirred at 500 rpm, and air was bubbled in the reaction volume at a rate of 8 mL min-1. 181 
2.7.Bioreaction with soluble TmCHMO and GDH-Tac biocatalysts  182 
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The reaction vessel was loaded with 10 mM of 3,3,5-trimethylcyclohexanone (47.4 μL), 250 183 
μM of NADP+ (5.9 mg), 350 mM of glucose, and 10% v v-1 of methanol (3 mL) for a total 184 
reaction volume of 30 mL. The reaction was started by the addition of a 3.07% v v-1 of soluble 185 
TmCHMO (0.921 mL of CFE containing 32.1 mg TmCHMO) and 4.87% v v-1 soluble GDH-186 
Tac (1.422 mL of CFE containing 65.8 mg soluble GDH-Tac). An additional 10 mM of 187 
substrate (47.4 μL) was added every hour until a total of 140 mM of substrate.  188 
2.8.Reusability of immobilized TmCHMO and GDH-Tac biocatalysts  189 
The reaction vessel was loaded with 10 mM of 3,3,5-trimethylcyclohexanone (47.4 μL), 250 190 
μM of NADP+ (5.9 mg), 30 mM of glucose, and 10% v v-1 of methanol (3 mL) for a total 191 
reaction volume of 30 mL. The reaction was started by the addition of 5% v v-1 of immobilized 192 
TmCHMO (20 mg TmCHMO g-1 support, 1.605 g of supported enzyme corresponding to 32.1 193 
mg TmCHMO) and 5% v v-1 of immobilized GDH-Tac (29 mg GDH-Tac g-1 support, 1.605 g 194 
supported enzyme corresponding to 46.5 mg GDH-Tac). The substrate and product 195 
concentration were determined by GC-FID analysis in triplicate. At the end of the reaction, the 196 
immobilized TmCHMO and immobilized GDH-Tac were filtered and washed with buffer. 197 
New reaction medium containing 10 mM 3,3,5-trimethylcyclohexanone, 250 μM NADP+, 30 198 
mM glucose and 10% v v-1 of methanol was prepared; to which the immobilized TmCHMO 199 
and immobilized GDH-Tac rinsed with buffer were added to start the reaction. The supported 200 
enzymes were stored at 4 °C overnight after cycles 5 and 10. 201 
2.9.Reusability of the co-immobilized TmCHMO and GDH-Tac biocatalysts 202 
The reactions were performed in a similar fashion as for the immobilized TmCHMO and GDH-203 
Tac biocatalyst. The biocatalyst concentration was 5.4% v v-1 (18.4 mg TmCHMO and 9.1 mg 204 
GDH-Tac g-1 support, 1.74 g of supported co-immobilized enzymes corresponding to 32.1 mg 205 
of TmCHMO and 15.83 mg of GDH-Tac).  206 
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3. RESULTS AND DISCUSSION 207 
3.1.Biocatalyst immobilization on MANA-agarose support 208 
Our goal was the oxidation of 3,3,5-trimethylcyclohexanone using the thermostable TmCHMO 209 
(Figure 1). The NADPH cofactor was regenerated by applying GDH-Tac, which uses glucose 210 
as a sacrificial cosubstrate. For this, both enzymes were evaluated in their soluble form as well 211 
as immobilized on MANA-agarose (separately or co-immobilized).  212 
Firstly, the immobilization of TmCHMO and GDH-Tac on MANA-agarose was studied aiming 213 
to define the best conditions for the immobilization of the biocatalysts following two 214 
approaches: separate enzyme immobilization and co-immobilization. Aiming to characterize 215 
the immobilization processes these studies were performed at low activity loads to ensure no 216 
mass transfer limitations once the enzyme is immobilized in the support (Table 1). 217 
In order to obtain the highest immobilization yield and retained activity, the immobilization of 218 
TmCHMO on MANA-agarose was assayed testing two different N-(3-dimethylaminopropyl)-219 
N’-ethylcarbodiimide (EDC) concentrations (25 and 35 mM). EDC is added once the protein 220 
is ionically adsorbed to promote its covalent binding to the support. The results showed that 221 
TmCHMO was completely adsorbed after 0.25 h and 35 mM of EDC was selected as the most 222 
appropriate concentration allowing an immobilization yield of 93.0% and a retained activity of 223 
62.4% (Table 1).  224 
Regarding the immobilization of GDH-Tac, it was ionically adsorbed onto MANA-agarose 225 
after 0.5 h. In the second phase of the immobilization, EDC was introduced at different 226 
concentrations (1, 3, 5, 10, 15 and 20 mM) to promote the covalent binding of the enzyme to 227 
the support. Among the EDC concentrations tested, 10 mM was chosen as the optimum as it 228 
presented 78.7% immobilization yield and 57.1% retained activity (Table 1).  229 
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For the co-immobilization of TmCHMO and GDH-Tac, two EDC concentrations were tested, 230 
10 and 20 mM. These values were selected taking into account the results obtained in the 231 
previous immobilization studies. An EDC concentration of 10 mM was selected since GDH-232 
Tac retained activity was significantly affected by high EDC concentration.  233 
3.2.Reutilization of the immobilized biocatalysts and comparison with the soluble 234 
enzymes 235 
The soluble and immobilized biocatalysts were applied to the oxidation of 3,3,5-236 
trimethylcyclohexanone. Similarly to our previous studies with TmCHMO and this 237 
substrate,[15] it was necessary to control the pH during the reaction since each molecule of the 238 
substrate that was converted resulted in the formation of one molecule of D-gluconolactone 239 
which was hydrolyzed to gluconic acid and consequently increased the acidity of the reaction 240 
(Figure 1). Auto-titration of the reaction by addition of NaOH at 1 M ensured a constant pH 241 
throughout the reaction course. A co-solvent (10% v v-1 methanol) was added to aid the 242 
solubility of the substrate, which is rather limited in water. This co-solvent was selected based 243 
on our previous results showing that this co-solvent results in the fastest reaction rate compared 244 
to other tested organic co-solvents.[15]  245 
The oxidation of 3,3,5-trimethylcyclohexanone was first performed with both soluble 246 
TmCHMO and GDH-Tac using a TmCHMO load of 1.07 mg mL-1 of reaction medium and an 247 
enzyme ratio of 1:2.0 (mg TmCHMO mg GDH-Tac-1). Total conversion of the initial substrate 248 
(10mM) was achieved in 1 h. Once the initial substrate was completely consumed, a fed-batch 249 
strategy was applied by supplying an additional 10 mM of substrate to the reaction mixture 250 
every hour up to a total of 150 mM of 3,3,5-trimethylcyclohexanone. The results showed that, 251 
while the ketone was fully converted in 1 h for the first 3 substrate additions, the accumulation 252 
of unreacted substrate was observed for the rest of the reaction until a final substrate 253 
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concentration of about 100 mM (Figure 2a). This change in the enzymatic reaction rate was 254 
directly correlated to the amount of base needed to maintain the pH of the reaction, which is 255 
related to the amount of gluconic acid co-product formed and substrate converted (Figure 2b). 256 
The conversion for each addition was calculated and the obtained results are depicted in Figure 257 
3. A sharp decrease in conversion per substrate addition was observed until an average 258 
conversion of about 10% was observed. This was attributed to the loss of enzymatic activity 259 
during the reaction, but substrate inhibition of TmCHMO as a consequence of substrate 260 
accumulation in the reaction mixture probably also played a role. Product accumulation in the 261 
reaction media could also contribute to a decrease in subsequent conversions since BVMOs 262 
often exhibit product inhibition, as has been previously reported by other authors.[31,37,38] 263 
Process metrics were analyzed for the fed-batch strategy using soluble enzymes (Table 2). The 264 
total process time after 14 additions was 14.4 h with a final product amount of 0.308 g and a 265 
final unreacted substrate amount of 0.423 g. The biocatalyst yields reached 9.6 and 4.7 mg of 266 
product mg-1 of TmCHMO and GDH-Tac, respectively. 267 
The performance of the TmCHMO and GDH-Tac which were separately immobilized at high 268 
enzymatic loads was also studied. The TmCHMO immobilized derivative contained 20 mg of 269 
monooxygenase g-1 of support, while the GDH-Tac derivative contained 29 mg of GDH-Tac 270 
g-1 of support. Aiming to compare the results with the soluble enzymes, the reactions were 271 
carried out using the same load of TmCHMO (1.07 mg TmCHMO per mL of reaction). The 272 
ratio of TmCHMO/GDH-Tac was slightly lower (1:1.5) since it is determined by i) the 273 
maximum immobilized derivative that can be used (10% v v-1) to ensure a proper suspension 274 
and mixing and, ii) the enzymes load per mg of support obtained during the immobilization 275 
processes.  276 
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Separately immobilized derivatives were used in the biooxidation reaction, where the first cycle 277 
took about 1.33 hour to total substrate conversion (Figure 4a). The increase in reaction time for 278 
a total conversion of the substrate during the first cycle could be related to i) the lower amount 279 
of loaded GDH-Tac with the immobilized enzymes which could lead to the cofactor 280 
regeneration reaction being the limiting step or/and ii) diffusion limitations of the NADP(H) 281 
co-factor between the bead particles containing TmCHMO and GDH-Tac or /and iii) oxygen, 282 
glucose or 3,3,5-trimethylcyclohexanone mass transfer limitations due to the diffusional 283 
restriction of these molecules in the support particles. 284 
The operational stability of the biocatalysts was studied. At the end of the reaction, both 285 
immobilized enzymes were recovered and reused for conversion of additional substrate in the 286 
same reaction conditions. In total, the immobilized enzymes were reused up to 15 times aiming 287 
to compare the results with the data obtained using soluble enzymes where 14 additions were 288 
carried out (Figure 4b). Full conversion was obtained for the first 5 cycles, after which the 289 
conversion started to decrease slowly.  290 
The process metrics obtained using separately immobilized biocatalysts are shown in table 2. 291 
Even though the total reaction time of the process was 1.4-fold higher, the average final product 292 
amount (0.422 g) increased by 37 %. Moreover, the use of separately immobilized enzymes 293 
also improves the process performance by reducing in 2.1-fold the final unreacted substrate 294 
amount (0.199 g) and increasing the TmCHMO biocatalyst yield by 36%. The overall 295 
biocatalyst yield is increased by 74% due to the better performances obtained with the 296 
separately immobilized biocatalysts, despite the lower GDH-Tac biocatalyst loading (70% of 297 
the GDH-Tac loading of the reaction with the soluble enzymes). 298 
The performance of the enzymes that were co-immobilized at high loads was also studied 299 
(TmCHMO: 18.4 mg g-1 of support; GDH-Tac: 9.1 mg g-1 of support). In order to compare the 300 
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performance of the co-immobilized catalysts with the biocatalysts immobilized separately and 301 
the soluble enzymes, the amount of co-immobilized support used in the oxidation reaction was 302 
calculated so that the same amount of TmCHMO was applied in all cases (1.07 mg mL-1). The 303 
ratio TmCHMO/GDH-Tac in this case (1:0.5) was determined by the ratio obtained during the 304 
co-immobilization process, where both enzymes compete for the same support.  305 
For this bioconversion, the reaction time was 1.17 h until the full conversion of the substrate, 306 
17% higher compared to the soluble enzymes (Figure 5a). The higher reaction time compared 307 
to the soluble enzymes could be due to the lower GDH-Tac load or to mass diffusional 308 
restrictions, as already mentioned with the separately immobilized enzymes. However, even 309 
though lower TmCHMO/GDH-Tac ratio was used when co-immobilized derivatives were used 310 
(1:0.5) compared to the separately immobilized enzymes (1:1.5), the reaction time was 12% 311 
lower. Thus, the reduction of the reaction time of the co-immobilized derivative compared to 312 
the separately immobilized biocatalyst probably indicates that NADP(H) cofactor diffusional 313 
restrictions between bead particles is likely the main cause of reaction time increase when 314 
separately immobilized derivatives are used. 315 
The operational stability studies were also carried out with the co-immobilized derivative 316 
during 15 cycles (Figure 5b). Compared to the biocatalysts immobilized separately, the co-317 
immobilized biocatalysts performed much better with the re-uses. A substrate conversion of 318 
58% was achieved for the last cycle (15) compared to 39% substrate conversion obtained for 319 
the same cycle with the biocatalysts immobilized separately.  320 
Regarding the process metrics (Table 2), co-immobilization, in particular, proved to be the best 321 
option of this biotransformation with higher average conversion over all re-utilization cycles 322 
(83%) despite the lower concentration of GDH-Tac in the reaction. The highest biocatalyst 323 
yields and final average product amounts were achieved with the co-immobilized biocatalysts. 324 
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Comparing to the separately immobilized enzymes, all process metric analyzed were improved: 325 
1.14-fold decrease in total process time, a 1.3-fold increase in final average product amount, a 326 
1.4-fold decrease in the unreacted substrate, a 1.1-fold increase in average conversion, and a 327 
1.3-fold increase in TmCHMO biocatalyst yield. The GDH-Tac biocatalyst yield was improved 328 
by 3.7-fold because the experiment with the co-immobilized enzymes achieved the best 329 
performances with the lowest GDH-Tac loading. 330 
Compared to the soluble enzymes for which a fed-batch strategy was applied, even though the 331 
total process time was slightly increased, the final average product formed was improved in 332 
1.7-fold, the unreacted substrate amount decreased in 3-fold, the average final conversion was 333 
increased in 1.6-fold, and the total biocatalyst yield was 3.6-fold higher. These values prove 334 
the better performance of the co-immobilized enzymes in the target reaction studied compared 335 
to separately immobilized enzymes. 336 
4. CONCLUSIONS 337 
TmCHMO was successfully immobilized on a MANA-agarose support with the co-enzyme 338 
GDH-Tac to ensure co-factor regeneration. Both the enzymes immobilized separately and co-339 
immobilized displayed good retention of activity in repeated re-utilization for the oxidation of 340 
3,3,5-trimethylcyclohexanone. Co-immobilized proved to give the most efficient biocatalyst 341 
format, achieving the highest average conversion over 15 re-utilization cycles (83%) and a high 342 
significant improvement of 3.6-fold of the total biocatalyst yield compared to the soluble 343 
enzymes. Compared to the biocatalysts which were separately immobilized, a highest reaction 344 
rate was observed which was attributed to more efficient diffusion of the NADP(H) co-factor 345 
between the two enzymes immobilized on the same support. This work demonstrates that 346 
immobilized BVMOs are promising biocatalysts for the synthesis of lactones, and in particular 347 
polymeric building blocks.  348 
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 422 
Figure 1. Biocatalyzed oxidation of 3,3,5-trimethylcyclohexanone 1 with TmCHMO and 423 
GDH-Tac to give the regio-isomeric lactones 1a and 1b which can be polymerized by ring 424 
opening polymerization. The enzymes were either immobilized on a MANA-agarose or 425 
soluble.  426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
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Table 1. Overview of the characterization of the immobilization of TmCHMO and GDH-Tac 435 
on MANA-agarose under optimum conditions. 436 
Enzyme Offered enzyme 
load* 
Immobilization 
yield (%) 
Retained activity 
(%) 
TmCHMO 5 U g-1 of support  
(8 mg TmCHMO g-1 
of support) 
93.0 62.4 
GDH-Tac  5 U g-1 of support 
(3.7 mg GDH-Tac g-
1 of support) 
78.7 57.1 
Co-immobilized 
TmCHMO and 
GDH-Tac 
5 U g-1 of support of 
each enzyme 
79.4 (TmCHMO) 
96.5 (GDH-Tac) 
12.9 (TmCHMO) 
48.2 (GDH-Tac) 
*No substrate transfer limitations were found at this enzymatic load 437 
 438 
 439 
 440 
 441 
 442 
 443 
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444 
 445 
Figure 2. a) Reaction course of the conversion of 3,3,5-trimethylcyclohexanone with soluble 446 
TmCHMO and soluble GDH-Tac (TmCHMO/GDH-Tac 1:2.0) with the concentration of 447 
substrate (blue circles) and product (black squares). The total amount of substrate accumulated 448 
is shown with a pink dotted line. b) Profile of the volume of NaOH (1M) added during the 449 
course of the reaction. The pink dotted line indicates the initiation rate of NaOH addition. 450 
Reaction conditions: 10 mM of substrate initially + 10 mM every hour, 10% v v-1 methanol, 451 
3.07% v v-1 soluble TmCHMO (1.07 mg mL-1), 4.87% v v-1 soluble GDH-Tac (2.19 mg mL-452 
1), 350 mM glucose, 250 µM NADP+. 453 
 454 
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 455 
 456 
Figure 3. Sequential additions of substrate for the reaction with soluble TmCHMO and soluble 457 
GDH-Tac (TmCHMO/GDH-Tac 1:2.0) with conversion as a function of the number of 458 
substrate additions (conversion = 1-([sub]f/[sub]i) with [sub]f the substrate concentration before 459 
the next addition of substrate and [sub]i the substrate concentration after the last addition of 460 
substrate).  461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
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 470 
Table 2. Overview of the performances of TmCHMO and GDH-Tac biocatalysts for the 471 
oxidation of 3,3,5-trimethylcyclohexanone 472 
Biocatalyst 
format 
Ratio 
TmCHMO 
:GDH-Tac 
Total 
reaction 
time  
(h) 
Product 
formeda  
(g) 
Unreacted 
substratea 
 (g) 
Average 
convb  
(%) 
Biocatalyst yieldc  
(mg product/mg biocatalysts) 
TmCHMO GDH-Tac Total  
Soluble 1:2.0 14.4 0.308 0.423 51 9.6 4.7 3.1 
Immobilized 1:1.5 20.0 0.422 0.199 73 13.1 9.1 5.4 
Co-
immobilized 
1:0.5 17.5 0.538 0.138 83 16.8 34.0 11.2 
a Cumulated amount of product and unreacted substrate (sum of each cycle for the 473 
immobilized enzymes and value measured at the end of the reaction for the soluble enzymes) 474 
bAverage conversion calculated for 15 cycles for the immobilized enzymes and for 14 475 
additions for the soluble enzymes. c Biocatalyst yield = total mg of product/mg of biocatalyst 476 
(TmCHMO, GDH-Tac or TmCHMO + GDH-Tac). 477 
 478 
 479 
 480 
 481 
 482 
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 483 
Figure 4. Re-uses of TmCHMO and GDH-Tac immobilized on separate supports 484 
(TmCHMO/GDH-Tac 1:1.5) with a) reaction profile for cycles 1, 6, 10, 15; and b) substrate 485 
conversion after 1.33 hour for all cycles. The vertical dotted lines indicate overnight storage of 486 
the immobilized enzymes in buffer solution. Reaction conditions: 10 mM of substrate, 10% v 487 
v-1 methanol, 5% v v-1 immobilized TmCHMO, 5% v v-1 immobilized GDH-Tac, 30 mM 488 
glucose, 250 µM NADP+, 1.33 h reaction time.  489 
 490 
 491 
 492 
 493 
 494 
 495 
 496 
 497 
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 498 
Figure 5. Re-uses of co-immobilized TmCHMO and GDH-Tac (TmCHMO/GDH-Tac 1:2.0) 499 
with a) reaction profile for cycles 1, 6, 10, 15; and b) substrate conversion after 1.17 hour for 500 
all cycles. The vertical dotted lines indicate overnight storage of the immobilized enzymes in 501 
buffer solution. Reaction conditions: 10 mM of substrate, 10% v v-1 methanol, 5.4% v v-1 co-502 
immobilized TmCHMO and GDH-Tac, 30 mM glucose, 250 µM NADP+, 1.17 h reaction time.  503 
